Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

INTRODUCTION: This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-BCMA/CD16a bispecific antibody. METHODS: RO7297089 was administered weekly by intravenous infusion to patients with relapsed/refractory multiple myeloma. The starting dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Plesner, Torben, Harrison, Simon J., Quach, Hang, Lee, Cindy, Bryant, Adam, Vangsted, Annette, Estell, Jane, Delforge, Michel, Offner, Fritz, Twomey, Patrick, Choeurng, Voleak, Li, Junyi, Hendricks, Robert, Ruppert, Shannon M., Sumiyoshi, Teiko, Miller, Karen, Cho, Eunpi, Schjesvold, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063703/
https://www.ncbi.nlm.nih.gov/pubmed/36656461
http://dx.doi.org/10.1007/s44228-022-00023-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063703/
https://www.ncbi.nlm.nih.gov/pubmed/36656461
http://dx.doi.org/10.1007/s44228-022-00023-5

Ejemplares similares